Sage Therapeutics, Inc. is a pioneering biotechnology company that is making significant strides in developing innovative treatments for central nervous system disorders.

Supernus Pharmaceuticals has announced a definitive agreement to acquire Sage Therapeutics for $12.00 per share, bolstering its portfolio with the groundbreaking oral medicine ZURZUVAE for postpartum depression.